prikaz prve stranice dokumenta No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study
  Preuzmi
PDF 1.13 MB
Znanstveni rad - Izvorni znanstveni rad
No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study
Heliyon, 10 (2024), 12; e32827. https://doi.org/10.1016/j.heliyon.2024.e32827
Krečak, Ivan; Bačić, Josipa Antonija; Šimunić, Nevena; Bušac, Vesna; Pivac, Ljerka; Čubrić, Eva; Skelin, Marko; Lucijanić, Marko

Citirajte ovaj rad

Krečak, I., Bačić, J. A., Šimunić, N., Bušac, V., Pivac, Lj., Čubrić, E. ... Lucijanić, M. (2024). No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study. Heliyon, 10. (12). doi: 10.1016/j.heliyon.2024.e32827

Krečak, Ivan, et al. "No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study." Heliyon, vol. 10, br. 12, 2024. https://doi.org/10.1016/j.heliyon.2024.e32827

Krečak, Ivan, Josipa Antonija Bačić, Nevena Šimunić, Vesna Bušac, Ljerka Pivac, Eva Čubrić, Marko Skelin i Marko Lucijanić. "No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study." Heliyon 10, br. 12 (2024). https://doi.org/10.1016/j.heliyon.2024.e32827

Krečak, I., et al. (2024) 'No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study', Heliyon, 10(12). doi: 10.1016/j.heliyon.2024.e32827

Krečak I, Bačić JA, Šimunić N, Bušac V, Pivac Lj, Čubrić E, i sur.. No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study. Heliyon [Internet]. 11.06.2024. [pristupljeno 11.11.2024.];10(12). doi: 10.1016/j.heliyon.2024.e32827

I. Krečak, et al., "No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study", Heliyon, vol. 10, br. 12, Lipanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:314923. [Citirano: 11.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:314923
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study
AutorIvan Krečak
AutorJosipa Antonija Bačić
AutorNevena Šimunić
AutorVesna Bušac
AutorLjerka Pivac
AutorEva Čubrić
AutorMarko Skelin
AutorMarko Lucijanić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
The presence of steatotic liver disease (SLD) is associated with an increased cardiovascular risk in the general population. Chronic myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET) and polycythemia vera (PV), are characterized by clonal myeloproliferation, chronic inflammatory state, and increased cardiovascular morbidity and mortality. The aim of this single-center study was to analyze clinical associations and the potential prognostic impact of SLD in ET and PV patients. We retrospectively included 108 patients (64 ET and 44 PV); median age was 70.5 years (range 21–92), 68 (63 %) were females, and the median follow-up time was 69 months. Baseline SLD presence was defined ultrasonographically and was detected in 25 (23.1 %) patients. There were no associations of SLD with any of the clinical and laboratory patient characterictics. Also, baseline ultrasonographic presence of SLD did not have an impact on future thrombotic, bleeding and disease transformation risk, nor patient survival. None of the patients experienced signs of liver failure during the follow-up. In conclusion, the presence of SLD in ET and PV patients does not seem to have major clinical implications. Therefore, patients may be advised about the generally harmless nature of SLD when occurring in the MPN context.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaHeliyon
Brojčani podacivol. 10, br. 12, e32827
p-ISSN2405-8440
DOIhttps://doi.org/10.1016/j.heliyon.2024.e32827
URN:NBNurn:nbn:hr:184:314923
Datum objave publikacije2024-06-11
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S2405844024088583
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-11-11 13:12:40